Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma

Meiting Chen, Zhao Wang, Xiaojie Fang, Yuyi Yao, Quanguang Ren, Zegeng Chen, Ying Tian, Fei Pan, Xiaoqian Li, Zhiming Li, Qingqing Cai, He Huang and Tongyu Lin
Cancer Biology & Medicine August 2021, 18 (3) 833-840; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0314
Meiting Chen
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhao Wang
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaojie Fang
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuyi Yao
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quanguang Ren
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zegeng Chen
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Tian
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Pan
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoqian Li
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiming Li
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qingqing Cai
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
He Huang
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for He Huang
  • For correspondence: [email protected] [email protected]
Tongyu Lin
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
2Senior Ward/Phase I Clinical Trial Ward, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tongyu Lin
  • For correspondence: [email protected] [email protected]
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 18 no. 3 833-840
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2020.0314

Published By 
Cancer Biology & Medicine
History 
  • Received July 2, 2020
  • Accepted September 25, 2020
  • Published online August 1, 2021.

Copyright & Usage 
Copyright: © 2021, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Meiting Chen1,*,
  2. Zhao Wang1,*,
  3. Xiaojie Fang1,
  4. Yuyi Yao1,
  5. Quanguang Ren1,
  6. Zegeng Chen1,
  7. Ying Tian1,
  8. Fei Pan1,
  9. Xiaoqian Li1,
  10. Zhiming Li1,
  11. Qingqing Cai1,
  12. He Huang1⇑ and
  13. Tongyu Lin1,2⇑
  1. 1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
  2. 2Senior Ward/Phase I Clinical Trial Ward, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China
  1. Correspondence to: He Huang and Tongyu Lin, E-mail: huanghe{at}sysucc.org.cn and tongyulin{at}hotmail.com
View Full Text

Cited By...

  • 1 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 18 (3)
Cancer Biology & Medicine
Vol. 18, Issue 3
1 Aug 2021
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
Meiting Chen, Zhao Wang, Xiaojie Fang, Yuyi Yao, Quanguang Ren, Zegeng Chen, Ying Tian, Fei Pan, Xiaoqian Li, Zhiming Li, Qingqing Cai, He Huang, Tongyu Lin
Cancer Biology & Medicine Aug 2021, 18 (3) 833-840; DOI: 10.20892/j.issn.2095-3941.2020.0314

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
Meiting Chen, Zhao Wang, Xiaojie Fang, Yuyi Yao, Quanguang Ren, Zegeng Chen, Ying Tian, Fei Pan, Xiaoqian Li, Zhiming Li, Qingqing Cai, He Huang, Tongyu Lin
Cancer Biology & Medicine Aug 2021, 18 (3) 833-840; DOI: 10.20892/j.issn.2095-3941.2020.0314
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Conclusions
    • Supporting Information
    • Grant support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer
  • Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
  • Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial
Show more Original Article

Similar Articles

Keywords

  • Sporadic Burkitt lymphoma
  • modified chemotherapy
  • toxicity
  • R-CODOX-M/IVAC
  • adults

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2023 Cancer Biology & Medicine

Powered by HighWire